How to Increase NAD+ Levels: A Research-Based Overview

How to Increase NAD+ Levels: A Research-Based Overview of Current Approaches

Given the central role of NAD+ in energy metabolism, DNA repair, sirtuin signaling, and aging biology, researchers and clinicians have developed substantial interest in strategies that can raise cellular NAD+ levels. The evidence base for different approaches varies considerably in quality and mechanistic specificity. This article reviews what the research shows about the main strategies for increasing NAD+ — from direct supplementation and biosynthetic precursors to lifestyle interventions and targeted enzyme inhibition.

---

Why Raising NAD+ Is a Research Priority

The case for developing NAD+-boosting interventions rests on a convergence of findings: tissue NAD+ levels decline substantially with age; this decline is mechanistically linked to mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and increased inflammation; and in preclinical models, restoring NAD+ levels reverses several of these age-associated phenotypes.

The challenge is that cellular NAD+ cannot simply be obtained from food in meaningful amounts — dietary sources provide precursors, not ready-formed NAD+. And NAD+ molecules, when ingested, are largely broken down in the gut before they can be absorbed intact. Effective strategies for raising cellular NAD+ must therefore either deliver bioavailable precursors that cells can convert to NAD+ or inhibit the enzymes that consume NAD+ — or both.

For a foundational understanding of what NAD+ does and why its levels matter, see our complete guide to NAD+ function and mechanisms.

---

1. Direct NAD+ Supplementation

The most direct approach to raising cellular NAD+ is to provide NAD+ itself. In research settings, this typically involves intravenous or intraperitoneal administration (for animal studies) or intravenous infusion (in clinical research), bypassing the intestinal degradation that limits oral bioavailability.

Published research using intravenous NAD+ administration has demonstrated rapid restoration of blood NAD+ levels and significant metabolic effects. A study by Birkmayer (1991) and later work documenting clinical outcomes in addiction and fatigue models established early proof-of-concept for intravenous NAD+ delivery.

More recent research has focused on understanding the pharmacokinetics of direct NAD+ administration: how rapidly it is taken up by tissues, which tissues accumulate it most efficiently, how long elevated levels are sustained, and what metabolic consequences follow. These questions are particularly relevant for researchers designing dosing protocols for cell culture and animal studies.

Spartan Peptides provides NAD+ 750mg as a research compound for licensed investigators. The 750mg dose represents a widely used benchmark in published protocols, particularly for systemic restoration experiments in rodent models and for in vitro studies requiring physiologically relevant NAD+ concentrations. For detailed discussion of dose selection and protocol design, see our article on NAD+ dosing for research.

---

2. NAD+ Precursors: NMN and NR

Because NAD+ itself has limited oral bioavailability, the majority of research into practical NAD+ augmentation strategies has focused on precursor molecules — compounds that cells can convert to NAD+ via the salvage pathway.

NMN (Nicotinamide Mononucleotide)

NMN is one step removed from NAD+ in the salvage pathway: NMNAT enzymes convert NMN directly to NAD+. NMN can be absorbed across the intestinal epithelium via the transporter Slc12a8, which was identified by Imai and colleagues in 2019, resolving a longstanding question about NMN’s route into cells.

Animal studies of NMN supplementation have produced some of the most compelling data in the NAD+ field. Yoshino et al. (2011) demonstrated that NMN administered to aged mice raised NAD+ in multiple tissues and reversed age-associated metabolic decline including impaired insulin sensitivity and mitochondrial dysfunction. Subsequent studies showed NMN improved physical endurance, neurological function, and reproductive biology in aging mice. A key 2021 human trial by Yoshino et al. in Science found that oral NMN supplementation raised blood NAD+ levels and improved skeletal muscle insulin sensitivity in postmenopausal women with prediabetes.

NR (Nicotinamide Riboside)

NR (the nucleoside form of NMN, lacking the phosphate group) was identified as an NAD+ precursor by Bieganowski and Brenner in 2004. It enters cells via equilibrative nucleoside transporters and is phosphorylated to NMN by NRK enzymes, then converted to NAD+ by NMNAT.

NR has been the most extensively studied NAD+ precursor in human clinical trials. Multiple phase I/II trials have confirmed that oral NR supplementation raises blood NAD+ levels in a dose-dependent manner and is well-tolerated. Trials in populations including healthy older adults, Parkinson’s disease patients, and individuals with metabolic syndrome have documented NR-associated increases in NAD+ and, in some cases, improvements in relevant biomarkers.

Comparison between NMN and NR: the two precursors enter the salvage pathway at different points, potentially resulting in tissue-specific differences in efficacy. Both have shown efficacy in raising blood and tissue NAD+, but direct head-to-head comparisons in humans remain limited.

For a broader analysis of NAD+ precursor research and what the published data show, see our post on NAD+ supplementation research overview.

---

3. Lifestyle Factors That Influence NAD+ Levels

Several behaviors and physiological conditions substantially affect cellular NAD+ levels through effects on NAD+ synthesis, consumption, and enzymatic activity. These represent research-relevant variables that investigators must account for in experimental design.

Exercise

Physical exercise, particularly resistance exercise and high-intensity interval training, acutely and chronically increases NAD+ levels in skeletal muscle. The mechanism involves multiple pathways: exercise increases NAMPT expression in muscle tissue, elevating the rate-limiting step in the salvage pathway; exercise activates AMPK, which stimulates NAMPT transcription; and exercise increases mitochondrial biogenesis through PGC-1α activation, increasing mitochondrial NAD+ demand and driving increased NAD+ synthesis.

Regular exercise also protects against some of the age-related decline in muscle NAD+ levels, partially through maintaining NAMPT expression. In sedentary aging mice, NAMPT expression in muscle declines substantially; in exercised mice, this decline is attenuated.

Caloric Restriction and Fasting

Caloric restriction (CR) — reduction of caloric intake without malnutrition — is the most reproducible intervention for extending lifespan in model organisms. Much of CR’s effect on longevity appears to be mediated through sirtuin activation, which requires elevated NAD+. How does CR raise NAD+?

Multiple mechanisms have been proposed. CR reduces PARP activation by decreasing the metabolic rate and oxidative stress that drive DNA damage. CR induces AMPK, which upregulates NAMPT. CR also shifts the NADH/NAD+ ratio — by reducing substrate availability, the electron transport chain works to oxidize NADH, increasing the relative proportion of NAD+. Time-restricted feeding and intermittent fasting protocols produce similar effects.

Notably, the beneficial effects of CR on longevity in rodents are substantially blunted in animals with reduced SIRT1 activity, suggesting that NAD+-sirtuin signaling is a primary effector pathway for CR’s benefits.

Circadian Rhythm Regulation

NAD+ metabolism is deeply intertwined with the circadian clock. NAMPT expression oscillates with a 24-hour period driven by the CLOCK:BMAL1 complex. SIRT1 is also a core component of the circadian clock machinery — it deacetylates BMAL1 and PER2, affecting the period and amplitude of circadian oscillations. This creates a bidirectional relationship: the clock drives NAMPT expression and NAD+ availability, and NAD+ through SIRT1 feeds back to regulate clock gene expression.

Disruption of circadian rhythms — by shift work, irregular sleep, or age-related weakening of circadian amplitude — reduces the peak levels of NAMPT expression and NAD+, contributing to the overall NAD+ decline observed with aging. Maintaining regular sleep-wake cycles and light exposure patterns is therefore a research-relevant variable for studies examining NAD+ biology.

---

4. CD38 Inhibition: Reducing the Drain

Rather than increasing NAD+ synthesis, another strategy for raising cellular NAD+ levels is to reduce consumption by the most profligate NAD+-consuming enzyme: CD38.

As reviewed by Chini and colleagues (2017), CD38 expression and activity increase with age and are further elevated by inflammatory stimuli. Genetic ablation of CD38 in mice substantially preserves NAD+ levels during aging and confers metabolic benefits. The question is whether pharmacological CD38 inhibition could achieve similar effects.

Apigenin

Apigenin is a plant-derived flavone found in parsley, celery, chamomile, and other plants. It was identified by Escande and colleagues (2013) as a competitive inhibitor of CD38, with IC₅₀ values in the low micromolar range in cell-free assays. In cell culture studies, apigenin treatment raised cellular NAD+ levels and activated SIRT1. In obese mice, apigenin treatment improved metabolic parameters including glucose tolerance, a result attributed at least in part to NAD+ preservation and sirtuin activation.

Quercetin

Quercetin, another flavone abundant in onions, apples, and other plant foods, also inhibits CD38 with similar potency to apigenin. The combination of CD38 inhibition (via quercetin or apigenin) and NAD+ precursor supplementation has been proposed as a synergistic approach, since reducing NAD+ degradation while increasing synthesis could produce larger elevations in steady-state NAD+ than either approach alone.

Research using CD38 inhibitors in combination with NMN or NR is ongoing, with some data suggesting additive or synergistic effects on tissue NAD+ elevation in rodent models.

---

5. NAMPT Activators

A more targeted approach to increasing NAD+ synthesis involves activating NAMPT, the rate-limiting enzyme in the salvage pathway. P7C3, a compound identified in a screen for neuroprotective agents, was found to have NAMPT-activating properties in neuronal cells and has been studied in models of neurodegeneration and traumatic brain injury. SBI-797812 is a more recently characterized direct NAMPT activator that has shown efficacy in raising NAD+ in cell culture and rodent models.

These compounds remain primarily research tools, but they illustrate the principle that targeting the supply side of NAD+ metabolism — rather than just supplementing precursors — may represent a viable strategy for tissue-specific NAD+ augmentation.

---

Comparison of Approaches

The various strategies for raising NAD+ differ in mechanism, evidence base, route of administration, and tissue distribution:

• Direct NAD+ (e.g., NAD+ 750mg, IV/IP in research): Rapid, systemic elevation; relevant for cell culture and acute animal experiments; limited oral bioavailability
• NMN (oral): Strong preclinical data; direct entry to salvage pathway; confirmed human efficacy for blood NAD+ elevation; increasingly studied for tissue-specific effects
• NR (oral): Most human trial data; confirmed blood NAD+ elevation; good safety profile; tissue distribution broadly similar to NMN
• Exercise: Raises muscle NAD+ through NAMPT upregulation; effects sustained with regular activity; no pharmacological intervention required
• Caloric restriction/fasting: Reduces PARP-mediated NAD+ consumption; improves NADH/NAD+ ratio; activates AMPK-NAMPT axis; well-supported in model organisms
• CD38 inhibitors (apigenin/quercetin): Reduce NAD+ degradation; potentially synergistic with precursors; primarily studied in cell culture and rodent models

For more on how these mechanisms connect to aging biology, see our post on NAD+ and cellular aging research.

---

Frequently Asked Questions

---

Research Disclaimer: The information presented in this article is intended for educational and research purposes only. NAD+ compounds discussed on this page are intended for use in licensed laboratory and research settings by qualified professionals. They are not approved for human consumption, are not dietary supplements, and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. All research involving these compounds must be conducted in compliance with applicable laws, regulations, and institutional guidelines. Spartan Peptides makes no claims regarding the safety or efficacy of these compounds in humans.